
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a data-driven healthcare technology company with a strong global presence and a focus on recurring customer revenue. Despite facing competition and potential risks, their partnerships and advancements in new applications make them a strong contender in the market. However, as they rely on external funding and have faced challenges in the past, investors should closely monitor their financials and expansion plans.
Bears say
Sophia Genetics is a healthcare technology company that offers a cloud-based platform for data-driven medicine and life sciences research. While the market potential for such technology is significant at $40B, SOPHiA Genetics is still experiencing losses and does not expect to approach profitability until 2026. Additionally, there are risks to consider, such as competition and cybersecurity breaches. Despite recent partnerships and customer acquisitions, the company will need to see continued growth and cost control in order to justify its current stock price.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares